InvestorsHub Logo
Followers 195
Posts 11247
Boards Moderated 0
Alias Born 11/29/2007

Re: 654321 post# 3952

Monday, 04/10/2017 8:52:32 AM

Monday, April 10, 2017 8:52:32 AM

Post# of 7559
"Geron expects the longer-term data from the trial, potential health authority feedback, and the totality of imetelstat program information, including an assessment of the evolving treatment landscape in MF and the potential application of imetelstat in multiple hematologic malignancies, including MDS, will inform Janssen's decision whether to continue development of imetelstat in relapsed or refractory MF."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News